These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27748045)

  • 1. A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
    Ibrahim N; Buchbinder EI; Granter SR; Rodig SJ; Giobbie-Hurder A; Becerra C; Tsiaras A; Gjini E; Fisher DE; Hodi FS
    Cancer Med; 2016 Nov; 5(11):3041-3050. PubMed ID: 27748045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
    DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
    Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
    Rathkopf DE; Picus J; Hussain A; Ellard S; Chi KN; Nydam T; Allen-Freda E; Mishra KK; Porro MG; Scher HI; Wilding G
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):537-44. PubMed ID: 23820963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
    Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
    Sharma S; Beck J; Mita M; Paul S; Woo MM; Squier M; Gadbaw B; Prince HM
    Invest New Drugs; 2013 Aug; 31(4):974-85. PubMed ID: 23377661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
    Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
    Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.
    de Marinis F; Atmaca A; Tiseo M; Giuffreda L; Rossi A; Gebbia V; D'Antonio C; Dal Zotto L; Al-Batran SE; Marsoni S; Wolf M
    J Thorac Oncol; 2013 Aug; 8(8):1091-4. PubMed ID: 23857399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
    PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
    Rathkopf D; Wong BY; Ross RW; Anand A; Tanaka E; Woo MM; Hu J; Dzik-Jurasz A; Yang W; Scher HI
    Cancer Chemother Pharmacol; 2010 May; 66(1):181-9. PubMed ID: 20217089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
    Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
    Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.
    Fukutomi A; Hatake K; Matsui K; Sakajiri S; Hirashima T; Tanii H; Kobayashi K; Yamamoto N
    Invest New Drugs; 2012 Jun; 30(3):1096-106. PubMed ID: 21484248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panobinostat for the treatment of acute myelogenous leukemia.
    Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
    Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R; Anderson KC; Lonial S
    Leuk Lymphoma; 2012 Sep; 53(9):1820-3. PubMed ID: 22288662
    [No Abstract]   [Full Text] [Related]  

  • 15. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.
    Ghobrial IM; Campigotto F; Murphy TJ; Boswell EN; Banwait R; Azab F; Chuma S; Kunsman J; Donovan A; Masood F; Warren D; Rodig S; Anderson KC; Richardson PG; Weller E; Matous J
    Blood; 2013 Feb; 121(8):1296-303. PubMed ID: 23287861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
    Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
    Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
    Duvic M; Dummer R; Becker JC; Poulalhon N; Ortiz Romero P; Grazia Bernengo M; Lebbé C; Assaf C; Squier M; Williams D; Marshood M; Tai F; Prince HM
    Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
    Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
    Morita S; Oizumi S; Minami H; Kitagawa K; Komatsu Y; Fujiwara Y; Inada M; Yuki S; Kiyota N; Mitsuma A; Sawaki M; Tanii H; Kimura J; Ando Y
    Invest New Drugs; 2012 Oct; 30(5):1950-7. PubMed ID: 21964801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.